Stock Ratings / Health Care / INMB / financials

IMA (24) LONA (42) TIL (51) CRBU (43) ⌘ Pro Terminal →

INmune Bio Inc. (INMB) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$1.60 +4.58% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.61

INmune Bio Inc. (INMB) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $44.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.61 (+0.63%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-5.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for INMB)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (45/100 Composite)

🔍 WHY INMB SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+13/20 pts (29% of score)

FRED Regime × Technicals: 34% of 52W Range • RSI-14 at 34.5 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+12/20 pts (27% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$1.89-16.9% Next Q

Q2 (-2Q)

Grade C-$1.57-7% Next Q

Q3 (-1Q)

Grade D$1.46+9.6% Next Q

Current

Grade D$1.60-6.3% Hist 90D α

Trajectory: C- (53) → D (45)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a INMB Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While INMB currently carries a cautious 45/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.99) and Max Pain ($1.68) forces dealer call-delta covering toward $2.73.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $INMB• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “INMB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 45%NO 55%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How INMB Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $155.0K

FY24

Rev $14.0K

FY25

Rev $50.0K

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$50.0K	52%	-80%	-$46.0M	-$23.6M	-45%
FY 2024	$14.0K	52%	-80%	-$42.0M	-$33.4M	-45%
FY 2023	$155.0K	52%	-80%	-$30.0M	-$12.0M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring INMB)

✓Walkthrough of INMB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

INMB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +11.89%📐 HORIZONTAL RANGE

2026-10-30O $1.53H $1.60L $1.43C $1.60VOL 183.9K

RES: $2.99SUP: $1.39SMA50: $1.99SMA200: $1.64

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

INMB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 INMB Butterfly Map → + Track INMB →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on INMB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for INMB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for INMB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INMB)

Health Care Rank #488 of 1016 ⚔️ IMA vs INMB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (INMB vs. IMA, LONA, TIL, CRBU)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, INmune Bio Inc. (INMB) ranks #488 by composite RQD confidence (45/100, grade D) and #766 by equity capitalization ($44.4M). Within this direct 5-issuer industry benchmark cohort, INMB leads on earnings valuation at N/A trailing P/E, while INMB leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. TIL currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with INMB at 45/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
INMB ACTIVE INmune Bio Inc.	D	45/100	—	—	-35.0%	+4.58%	$44.4M	Benchmark Subject
IMA ImageneBio Inc.	E	24/100	—	—	-35.0%	-3.57%	$46.0M	/ima-vs-inmb →
LONA LeonaBio Inc.	D-	42/100	—	—	-35.0%	-1.01%	$46.3M	/lona-vs-inmb →
TIL Instil Bio Inc.	D	51/100	—	—	-35.0%	+0.52%	$46.3M	/til-vs-inmb →
CRBU Caribou Biosciences Inc.	D-	43/100	—	—	-35.0%	-9.07%	$47.7M	/crbu-vs-inmb →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001711754

In its most recent audited fiscal period (FY2025, filed 2025-12-31), INmune Bio Inc. (INMB) reported GAAP revenue of $50.0K (+257.1% vs. FY2024 revenue of $14.0K , and -67.7% cumulative change since FY2023) , GAAP net income of -$46.0M, operating cash flow of -$22.6M, and free cash flow of -$23.6M (+29.2% YoY). On the balance sheet, INMB closed FY2025 with $32.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$50.0K	-$46.0M	-$22.6M	-$23.6M	$32.4M	—
FY2024 (FY)	2024-12-31	$14.0K	-$42.0M	-$33.4M	-$33.4M	$39.6M	—
FY2023 (FY)	2023-12-31	$155.0K	-$30.0M	-$12.0M	-$12.0M	—	—

3. INMB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is INMB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, INmune Bio Inc. (NASDAQ: INMB) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $1.60 (+4.58% 1D, market cap $44.4M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, INMB ranks #488 in composite RQD confidence.

How does INMB compare to IMA and LONA in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), INMB carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IMA (ImageneBio Inc.) holds a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $46.0M) and LONA (LeonaBio Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $46.3M). Among the 5-stock peer group, INMB leads on earnings multiple (N/A) while INMB leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for INMB?

Per INMB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001711754), INmune Bio Inc. generated $50.0K in revenue (+257.1% YoY), -$46.0M in net income, and -$23.6M in free cash flow against $32.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is INMB trading relative to its 50-day, 200-day, and 52-week technical levels?

INMB last traded at $1.60 (+4.58% on volume of 185,890 shares), positioning the stock -19.60% below its 50-day simple moving average ($1.99) and -2.44% below its 200-day simple moving average ($1.64). Across its 52-week range of $1.09 to $2.60, INMB sits at the 33.8% percentile with a 14-day RSI of 34.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.40 to $1.80).

INMB Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is INmune Bio Inc. (INMB)?

In FY 2025 (10-K), INMB converted $1.0M of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: INMB RQD Cockpit INMB 12M Forecast INMB Earnings & Move INMB Dividends & DRIP INMB Insiders & 13F INMB Whale Options INMB Profit Sankey INMB News & Why